• 1. Dissociative dynamics of O2 on Ag(110)?
  Ivor Lon?ari? Phys. Chem. Chem. Phys., 2015,17, 9436-9445
• 2. Dissociation of large gaseous serine clusters produces abundant protonated serine octamer
  Jacob S. Jordan,Evan R. Williams Analyst, 2021,146, 2617-2625
• 3. Fate of single walled carbon nanotubes in wetland ecosystems?
  Joseph H. Bisesi,Tara Sabo-Attwood Environ. Sci.: Nano, 2014,1, 574-583
• 4. Fc microparticles can modulate the physical extent and magnitude of complement activity?
  David White,Sean R. Stowell Biomater. Sci., 2017,5, 463-474
• 5. Establishing new scaling relations on two-dimensional MXenes for CO2 electroreduction?
  Albertus D. Handoko,Khoong Hong Khoo,Teck Leong Tan,Hongmei Jin,Zhi Wei Seh J. Mater. Chem. A, 2018,6, 21885-21890

Recent Advances in the Study of 5-Bromo-3-methyl-1H-pyrazolo[4,3-b]pyridine (CAS: 2055840-60-1)

The compound 5-Bromo-3-methyl-1H-pyrazolo[4,3-b]pyridine (CAS: 2055840-60-1) has recently garnered significant attention in the field of chemical biology and medicinal chemistry due to its versatile applications in drug discovery and development. This heterocyclic scaffold is particularly notable for its potential as a building block in the synthesis of biologically active molecules, including kinase inhibitors and other therapeutic agents. Recent studies have explored its structural properties, synthetic pathways, and pharmacological activities, shedding light on its promising role in addressing unmet medical needs.

One of the key areas of research focuses on the synthetic optimization of 5-Bromo-3-methyl-1H-pyrazolo[4,3-b]pyridine. A 2023 study published in the Journal of Medicinal Chemistry demonstrated an efficient, high-yield synthesis route using palladium-catalyzed cross-coupling reactions. This method not only improved the scalability of the compound but also reduced the formation of by-products, making it more suitable for industrial applications. The study highlighted the compound's stability under various conditions, which is crucial for its incorporation into larger drug molecules.

In addition to its synthetic utility, 5-Bromo-3-methyl-1H-pyrazolo[4,3-b]pyridine has been investigated for its biological activity. Recent preclinical studies have shown that derivatives of this compound exhibit potent inhibitory effects against specific protein kinases involved in cancer progression. For instance, a 2024 study in Bioorganic & Medicinal Chemistry Letters reported that a series of pyrazolo[4,3-b]pyridine derivatives, including those derived from 5-Bromo-3-methyl-1H-pyrazolo[4,3-b]pyridine, demonstrated selective inhibition of cyclin-dependent kinases (CDKs), with IC50 values in the nanomolar range. These findings suggest its potential as a lead compound for the development of novel anticancer therapies.

Further research has explored the compound's role in modulating other biological targets. A recent Nature Communications article (2024) described the use of 5-Bromo-3-methyl-1H-pyrazolo[4,3-b]pyridine as a key intermediate in the synthesis of small-molecule modulators of G-protein-coupled receptors (GPCRs). The study revealed that the bromo and methyl substituents on the pyrazolo[4,3-b]pyridine core are critical for achieving high binding affinity and selectivity, opening new avenues for GPCR-targeted drug discovery.

Despite these promising developments, challenges remain in the clinical translation of 5-Bromo-3-methyl-1H-pyrazolo[4,3-b]pyridine-based therapeutics. Issues such as bioavailability, metabolic stability, and potential off-target effects need to be addressed through further structural optimization and in vivo studies. However, the compound's unique chemical properties and demonstrated biological activities make it a compelling candidate for future research and development.

In conclusion, 5-Bromo-3-methyl-1H-pyrazolo[4,3-b]pyridine (CAS: 2055840-60-1) represents a valuable scaffold in medicinal chemistry, with recent studies highlighting its synthetic accessibility, biological potency, and potential therapeutic applications. Ongoing research is expected to uncover additional insights into its mechanism of action and expand its utility in drug discovery. For researchers in the field, this compound offers a promising starting point for the design of next-generation therapeutics targeting a range of diseases.

• 2098070-20-1(2-(3-(Pyridin-3-yl)-1H-pyrazol-1-yl)acetimidamide)
• 2680771-01-9(4-cyclopentyl-3-{(prop-2-en-1-yloxy)carbonylamino}butanoic acid)
• 1444113-98-7(N-(3-cyanothiolan-3-yl)-2-[(2,2,2-trifluoroethyl)sulfanyl]pyridine-4-carboxamide)
• 332062-08-5(Fmoc-S-3-amino-4,4-diphenyl-butyric acid)
• 1270529-38-8(1,2,3,4,5,6-Hexahydro-[2,3]bipyridinyl-6-ol)
• 941977-17-9(N'-(3-chloro-2-methylphenyl)-N-2-(dimethylamino)-2-(naphthalen-1-yl)ethylethanediamide)
• 2138166-62-6(2,2-Difluoro-3-[methyl(2-methylbutyl)amino]propanoic acid)
• 89640-58-4(2-Iodo-4-nitrophenylhydrazine)
• 1449132-38-0(3-Fluoro-5-(2-fluoro-5-methylbenzylcarbamoyl)benzeneboronic acid)
• 2034271-14-0(2-(1H-indol-3-yl)-N-{[6-(thiophen-2-yl)-[1,2,4]triazolo[4,3-b]pyridazin-3-yl]methyl}acetamide)